The expert in urologic oncology spoke about the advancements made in 2020, as well as areas of prostate cancer care which he believes remain to be improved.
Each year cancer therapies continue to improve, and this year was no different with regard to prostate cancer research.
From advancements such as the FDA approval of the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer, Gallium 68 PSMA-11 (Ga 68 PSMA-11), to the continued identification of disparities and how to possibly mitigate them, prostate cancer exploration persists.
In an interview with CancerNetwork®, Judd W. Moul, MD, FACS, a urologic oncologist at Duke Cancer Center and Duke Urology Clinic, discussed the latest advancements in prostate cancer and what areas of care he believes could still be improved.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.